Farmers & Merchants Investments Inc. Has $1.58 Million Stock Holdings in Kenvue Inc. (NYSE:KVUE)

Farmers & Merchants Investments Inc. increased its stake in shares of Kenvue Inc. (NYSE:KVUE) by 1.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 73,910 shares of the company’s stock after buying an additional 1,000 shares during the period. Farmers & Merchants Investments Inc.’s holdings in Kenvue were worth $1,578,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Grove Bank & Trust lifted its position in shares of Kenvue by 438.4% during the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after purchasing an additional 947 shares in the last quarter. Riverview Trust Co bought a new position in Kenvue in the 3rd quarter worth approximately $30,000. Geneos Wealth Management Inc. acquired a new position in Kenvue during the 4th quarter worth $29,000. Ashton Thomas Securities LLC bought a new position in Kenvue in the 3rd quarter valued at $35,000. Finally, Fortitude Family Office LLC increased its stake in shares of Kenvue by 106.6% in the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after buying an additional 777 shares during the period. Institutional investors own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Canaccord Genuity Group cut their price target on Kenvue from $27.00 to $24.00 and set a “buy” rating on the stock in a research note on Friday. Bank of America upped their target price on shares of Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research report on Tuesday, October 22nd. Piper Sandler upgraded shares of Kenvue from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $21.00 to $26.00 in a research report on Monday, January 6th. Barclays cut their price objective on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a report on Friday, January 17th. Finally, UBS Group lowered their target price on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a report on Friday. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $23.00.

Kenvue Stock Up 2.2 %

NYSE:KVUE opened at $20.23 on Friday. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46. The stock has a 50-day moving average price of $21.54 and a two-hundred day moving average price of $21.95. The stock has a market cap of $38.79 billion, a price-to-earnings ratio of 38.17, a PEG ratio of 2.16 and a beta of 1.45. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, equities analysts expect that Kenvue Inc. will post 1.05 earnings per share for the current year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be issued a dividend of $0.205 per share. The ex-dividend date is Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 4.05%. Kenvue’s payout ratio is 154.72%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.